BeiGene Inks Potential $1.3B Deal with Ensem for Early-Stage CDK2 Inhibitor

cafead

Administrator
Staff member
  • cafead   Nov 21, 2023 at 12:02: PM
via BeiGene on Tuesday announced that it would acquire an exclusive global license to Ensem Therapeutics’ investigational and potentially best-in-class oral CDK2 inhibitor EXT-197, which is being developed for cancer.

article source
 

<